Who Paid My Doc
Vipul Joshi
Brandon, FL Medical Doctor
NPI 1003868993 CMS profile 45487
1355 Providence Rd, Brandon, FL 33511
General payments
$42,600
Research payments
$51,225
Ownership & investment interest
$0
Research they led as principal investigator
$3,014,956
Through program year 2025, Vipul Joshi of Brandon, FL is reported in the CMS Open Payments database as having received $42,600 across 1,500 general payments and $51,225 in research payments paid to them. Separately, studies naming them as principal investigator received $3,014,956 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,573 | 173 | |
| 2025 | Research | $27,050 | 2 | |
| 2024 | General | $3,763 | 220 | |
| 2023 | General | $4,458 | 200 | |
| 2023 | Research | $2,009 | 14 | |
| 2022 | General | $6,407 | 215 | |
| 2021 | General | $3,287 | 190 | |
| 2020 | General | $3,582 | 198 | |
| 2020 | Research | $2,302 | 11 | |
| 2019 | General | $16,530 | 304 | |
| 2019 | Research | $19,864 | 10 |
Beside peers
- Vipul Joshi
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Vipul Joshi were reported at $4,573. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Vipul Joshi | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $16,530 | $197 | $63–$719 | $163 |
| 2020 | $3,582 | $126 | $38–$436 | $114 |
| 2021 | $3,287 | $151 | $45–$537 | $132 |
| 2022 | $6,407 | $175 | $53–$607 | $149 |
| 2023 | $4,458 | $183 | $57–$637 | $160 |
| 2024 | $3,763 | $185 | $56–$647 | $164 |
| 2025 | $4,573 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
499
Drug cost
$283,106
Branded share of claims
9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 17 | $156,596 | |
| Humira Pen Adalimumab | Brand | 15 | $118,543 | |
| Pregabalin | Generic | 122 | $4,015 | |
| Tramadol Hcl | Generic | 284 | $2,273 | |
| Hydroxychloroquine Sulfate | Generic | 23 | $1,209 | |
| Methotrexate Methotrexate Sodium | Brand | 13 | $273 | |
| Duloxetine Hcl | Generic | 13 | $170 | |
| Clonazepam | Generic | 12 | $27 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 77 billing codesPaid by Medicare
$6,479,663
Medicare patients
1,030
Services billed
659,242
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 69% | |
| Chronic kidney disease | 33% | |
| Ischemic heart disease | 31% | |
| Depression | 31% | |
| Diabetes | 27% | |
| COPD | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 65 | 42,325 | $1,434,868 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 | Office | 88 | 310,400 | $1,125,728 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 110 | 124,530 | $1,061,444 |
| Injection, denosumab, 1 mg J0897 | Office | 342 | 34,140 | $701,481 |
| Injection, tocilizumab, 1 mg J3262 | Office | 28 | 91,363 | $430,320 |
| Injection, rituximab, 10 mg J9312 | Office | 13 | 4,500 | $276,341 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 31 | 24,150 | $219,461 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 15 | 4,350 | $108,055 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 26 | 130 | $631 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 19 | 96 | $445 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 28 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KRYSTEXXA |
|
$659 | — | — |
| Cimzia |
|
$317 | — | 310,400 |
| SAPHNELO |
|
$303 | — | — |
| RINVOQ |
|
$254 | — | — |
| EVENITY |
|
$193 | — | 124,530 |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 28 with PatronRecords
1,537 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.